Enalapril Maleate (MK-421), a Potent, Nonsulfhydryl Angiotensin-Converting Enzyme Inhibitor: Absorption, Disposition, and Metabolism in Man
- 1 January 1983
- journal article
- research article
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 14 (1) , 99-110
- https://doi.org/10.3109/03602538308991383
Abstract
Animal studies (particularly in dogs) on enalapril maleate have served to predict the patterns of absorption and elimination observed in man. Enalapril is more readily absorbed in man than the active inhibitor form MK-422. Estimates of minimum absorption of enalapril are of the order of 60-70%, based on urinary recovery. Metabolism of enalapril to MK-422 appears to be largely a postabsorptive process. From urinary recovery data, a minimum of 43% of a 10-mg dose of enalapril is available as MK-422. Excretion of enalapril and MK-422 is principally renal. The excellent mass balance obtained in human studies precludes extensive metabolism beyond hydrolysis to MK-422. Data in hand suggest that any metabolism other than to MK-422 is of a trace nature.Keywords
This publication has 7 references indexed in Scilit:
- Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.British Journal of Clinical Pharmacology, 1981
- A new class of angiotensin-converting enzyme inhibitorsNature, 1980
- 2 Inhibitiors of Angiotensin-Converting EnzymeProgress in Medicinal Chemistry, 1980
- Captopril (SQ 14,225) (d-3-mercapto-2-methylpropanoyl-l-proline): A novel orally active inhibitor of angiotensin-converting enzyme and antihypertensive agentProgress in Cardiovascular Diseases, 1978
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977
- TRANSITION STATE ANALOG INHIBITORS AND ENZYME CATALYSISAnnual Review of Biophysics and Bioengineering, 1976
- Mechanisms regulating renin releasePhysiological Reviews, 1976